Prescribing information



Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

700k patients and counting globally across all indications*1,2


Image with the words Take control early with Cosentyx to help your adult PsO patients look, move and feel better

Image with the words Real-world evidence from BADBIR, one of the largest national psoriasis registries in the world

Image with the words Recommended by BAD as the first-line biologic for patients with PsO, with or without PsA



What difference can Cosentyx make for your adult patients?

Cosentyx has a well-established efficacy profile that offers your patients a chance to:





*Worldwide, across all licensed indications.1

BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drugs; IL, interleukin; MRI, magnetic resonance imaging; MTX, methotrexate; NICE, National Institute for Health and Care Excellence; NSAIDs, non-steroidal anti-inflammatory drugs; PASI, Psoriasis Area and Severity Index (PASI); PsA, psoriatic arthritis; QoL, quality of life.


  1. Rheumatology DOF UK 313.
  2. BADBIR. Available at: [Accessed June 2022].
  3. Cosentyx Summary of Product Characteristics.
  4. Yiu ZZN, et al. Br J Dermatol 2020;183(2):294–302.     
  5. Smith CH, et al. Br J Dermatol 2020;183(4):628–637.     
  6. Thaci D, et al. J Am Acad Dermatol 2015;73(3):400–409.     
  7. Langley RG, et al. NEJM 2014;371(4):326–338.     
  8. Blauvelt A, et al. J Am Acad Dermatol 2017;76(1):60–69.     
  9. Bissonnette R, et al. J Eur Acad Dermatol Venereol 2018;32:1507–1514.     
  10. Rheumatology DOF UK 215.     
  11. Mease P, et al. Ann Rheum Dis 2018;77(6);890–897.     
  12. Mease P, et al. ACR Open Rheum 2020;2(1):18–25.     
  13. Baraliakos X, et al. RMD Open 2019;5(2):e001005.     
  14. Feldman SR, et al. J Derm Treat 2020; doi:10.1080/09546634.2019.1708854.


Rate this content: 
Average: 2.5 (10 votes)
UK | June 2022 | 219676

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]